Fulcrum Pharma Plc.

Mr. Nemoto joined Fulcrum in June 2000. He assists the president of Fulcrum Pharma KK in the management of the operational activities of Fulcrum in Japan. Prior to joining Fulcrum, Mr. Nemoto held senior positions in clinical drug development in Japanese affiliates of Roche and the Japanese Grelan Co. Ltd. Most recently, he has been Assistant Project Leader for the Japanese development of an anti-obesity agent (Xenical ). He has also managed the clinical development of oncology agents in Japan (Herceptin and DMDC), as well as having responsibility for clinical development support for agents in other therapeutic areas (anti-viral, drug-delivery system of hormone, anti-hypertension and antibiotics). Mr. Nemoto gained a B.Sc. in Pharmacology at Tokyo College of Pharmacy.

Dr. Susick is responsible for nonclinical plan development and implementation at Fulcrum as well as leading project teams during the nonclinical phase. He joined Fulcrum in 2002 and has over 18 years experience in drug development. Dr. Susick received his undergraduate degree in Biology from Wayne State University and a Ph.D. in Toxicology from the University of Michigan. He is a certified Diplomate of the American Board of Toxicology. Following graduate training and a postdoctoral fellowship in toxicology at the University of Michigan, Bob began his pharmaceutical career in regulatory safety assessment at Parke-Davis/Warner-Lambert in 1986. He served as Study Director for general toxicology, reproductive, and genetic toxicology studies. He also served as toxicologist on discovery and development project teams including the team that identified Lipitor as a clinical candidate and advanced the molecule into early clinical trials. He joined Sphinx Pharmaceuticals in 1990 to establish the company's toxicology department as well as lead the company's first drug development team through Phase 2. Bob also established Sphinx's outsourcing model for conduct of nonclinical studies by CROs. After Lilly acquired Sphinx, Bob joined Lilly to manage the Investigative Toxicology Department, which consisted of 11 laboratories, 51 personnel, and an annual budget of over $ 6 million. He subsequently joined Lilly's Pharmaceutical Project Management Group where he led cross-functional project teams developing treatments for Alzheimer's disease and pain. In 2000, Bob joined Incara Pharmaceuticals as Vice President responsible for the company's cell therapy subsidiary and led the hepatic cell therapy project team to successful IND submission.

Dr. Walters is a founder member of Fulcrum and is responsible for the international regulatory strategy for Fulcrum projects. In addition, he manages the development and application of state-of-the-art knowledge management systems to maximize the efficiency of virtual teams and, in particular, to ensure high quality interactions with health authorities and customers. Prior to Fulcrum, Dr. Walters was a founder member of the virtual drug development company, Protodigm Ltd, where he was responsible for regulatory affairs and communication. In this role, he was responsible for setting and implementing the international regulatory strategy for all Protodigm projects. Dr. Walters managed teams of regulatory professionals as part of the virtual teams, and sponsored team-based writing and communication processes supported by state-of-the-art document management and dossier submission systems. Prior to joining Protodigm, Dr. Walters worked for Roche for 10 years in the UK and at corporate headquarters in Switzerland, in Regulatory Affairs, Product Management, Clinical Documentation and Clinical Pharmacology. Dr. Walters has a B.Sc. (Hons) and Ph.D. in Physiology from University of Leeds.

Mr. Smith is responsible for financial matters associated both with running the company and specific projects. Mr. Smith qualified as a Chartered Accountant with KPMG Peat Marwick in Leeds in 1979 and then specialised in corporate tax with Robson Rhodes. He was Finance Director of Spong Holdings plc before establishing his own specialist tax consultancy in 1987, which he continues to date.

Professor Sir Charles George is Medical Director of the British Heart Foundation and former Chairman of the Joint Formulatory Committee, responsible for overseeing the production of the British National Formulary. He is Emeritus Professor of Clinical Pharmacology at the University of Southampton, where he has served as Dean from 1993 to 1998. He has also been a Director of Southampton Innovations Limited, the company responsible for capitalizing on the intellectual property rights of innovations arising from within Southampton University. Sir Charles has served on numerous Department of Health committees and the Committee on Review of Medicines. He has been a consultant to several major pharmaceutical companies. His distinguished career in medicine was recognized with a Knighthood in 1998. His other honours include FFPM, FRSA and FmedSci.